Clinical Implications of Inflammation-Mediated Dysregulation of Glial Cell Fate: A Systematic Review for Early Brain Tumor Risk Detection and Improved Patient Outcomes

ObjectiveThis study aims to investigate how neuroinflammation alters gliogenic regulatory pathways and glial cell fate decisions, with a focus on identifying clinically relevant mechanisms that may increase susceptibility to glial-derived brain tumors. By linking inflammatory signaling to early disruptions in gliogenesis, this study seeks to inform future strategies for risk assessment, early detection, and potential therapeutic intervention in inflammation-associated neuro-oncology. BackgroundNeuroinflammation alters gliogenic signaling by disrupting key regulatory pathways such as FGFR3, JAK-STAT, STAT3, and others. This dysregulation affects glial cell differentiation and lineage decisions, contributing to impaired neurodevelopment and increased susceptibility to glial-derived brain tumors, particularly gliomas. Understanding these inflammatory mechanisms is essential for identifying early biomarkers, evaluating long-term tumor risk, and developing strategies to prevent or mitigate neuro-oncological outcomes in individuals with acute or chronic CNS inflammation. MethodsDatabases, including PubMed, MEDLINE, Google Scholar, and both open-access and subscription-based journals, were searched without date restrictions to investigate the brain inflammation induced disruption of gliogenic regulators (FGFR3, JAK-STAT, STAT3, S100, Hey1, HES1, DTX, IL-6, NF-{kappa}B, Neuregulin-1, MAPK/MEK, E2F/TCFL2, NFIX/Ephrins/Netrins) resulting in glial cell fate dysregulations and Its contribution to brain tumor risk. Studies meeting the criteria outlined in the methods section were systematically reviewed to address the research question. This study adheres to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. ResultsNeuroinflammation significantly alters gliogenic regulators, including FGFR3, JAK-STAT, STAT3, S100, IL-6, and NF-{kappa}B, disrupting normal glial maturation, migration, and lineage commitment. This leads to aberrant cell fate decisions, sustained proliferation, and genomic instability, conditions favorable for glioma initiation. Pro-inflammatory pathways, notably IL-6 and NF-{kappa}B, drive oxidative stress and cellular dysfunction, reinforcing the tumor-permissive environment. These insights point to the clinical relevance of inflammation-driven glial dysregulation in brain tumor pathogenesis. ConclusionDisruption of gliogenic regulators by neuroinflammation alters glial fate specification, promotes proliferative stress, and contributes to oncogenic transformation within the CNS. These findings emphasize the need to clinically monitor individuals with significant or recurrent brain inflammation for long-term neuro-oncological risks. Early recognition of these disturbances may guide risk stratification, surveillance, and development of anti-inflammatory or gliogenesis-targeted interventions to prevent glial-origin brain tumors.